Immune-related adverse events of COVID-19 vaccination in skin cancer patients receiving immune-checkpoint inhibitor treatment
To date, few data are available regarding Adverse events (AEs) in cancer patients who are vaccinated for coronavirus disease 2019 (COVID-19) while being actively treated with Immune-checkpoint inhibitors (ICIs). We aimed to assess the safety of COVID-19 vaccines approved in Germany. Specifically, we...
Gespeichert in:
| Hauptverfasser: | , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
23 December 2021
|
| In: |
Cancer immunology immunotherapy
Year: 2021, Jahrgang: 71, Heft: 8, Pages: 2051-2056 |
| ISSN: | 1432-0851 |
| DOI: | 10.1007/s00262-021-03133-w |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.1007/s00262-021-03133-w
|
| Verfasserangaben: | Sophia B. Strobel, Devayani Machiraju, Katharina A. Kälber, Jessica C. Hassel |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1847534716 | ||
| 003 | DE-627 | ||
| 005 | 20240328080441.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230606r20222021xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00262-021-03133-w |2 doi | |
| 035 | |a (DE-627)1847534716 | ||
| 035 | |a (DE-599)KXP1847534716 | ||
| 035 | |a (OCoLC)1389533438 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Strobel, Sophia |d 1985- |e VerfasserIn |0 (DE-588)1034652141 |0 (DE-627)746142005 |0 (DE-576)382291646 |4 aut | |
| 245 | 1 | 0 | |a Immune-related adverse events of COVID-19 vaccination in skin cancer patients receiving immune-checkpoint inhibitor treatment |c Sophia B. Strobel, Devayani Machiraju, Katharina A. Kälber, Jessica C. Hassel |
| 264 | 1 | |c 23 December 2021 | |
| 300 | |a 6 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 06.06.2023 | ||
| 520 | |a To date, few data are available regarding Adverse events (AEs) in cancer patients who are vaccinated for coronavirus disease 2019 (COVID-19) while being actively treated with Immune-checkpoint inhibitors (ICIs). We aimed to assess the safety of COVID-19 vaccines approved in Germany. Specifically, we investigated the frequency of general side effects and immune-related AEs of COVID-19 vaccination. A triage survey was used to collect the following information for patients with metastatic skin cancer: vaccine type, date of receipt of each dose of vaccine, and self-reported side effects. Clinical data were retrieved from the patients’ medical records. Of 130 patients with metastatic skin cancer, 89 patients were on immunotherapy and received COVID-19 vaccination. Of these 89 patients (median age: 64 years; 57 [64%] men), 89% had melanoma, and 71% received ICI therapy with a PD-1 antibody. Eighty-eight percent received an mRNA-based COVID-19 vaccination. The median follow-up time was 125 days after the first vaccination, and 84 days after the second. The most common observed side effects were mild to moderate pain at the injection site (40%), followed by fatigue (24%). Grade 3 irAEs were reported in eight patients, seven of whom were on nivolumab plus ipilimumab combination treatment. Of the 19 patients vaccinated within 72 h before/after ICI, five developed irAEs within 17 days (1-17 days). This small cohort study suggests that approved COVID-19 vaccinations are safe for use in cancer patients receiving ICIs. However, some precautions should be taken, especially regarding the timing of vaccination and ICI treatment. | ||
| 534 | |c 2021 | ||
| 650 | 4 | |a Adverse events | |
| 650 | 4 | |a Cancer patients | |
| 650 | 4 | |a COVID-19 vaccination | |
| 650 | 4 | |a Immune-checkpoint inhibitors | |
| 700 | 1 | |a Machiraju, Devayani |e VerfasserIn |0 (DE-588)1165195224 |0 (DE-627)1029355924 |0 (DE-576)510306586 |4 aut | |
| 700 | 1 | |a Kälber, Katharina |e VerfasserIn |0 (DE-588)1262091551 |0 (DE-627)1809475007 |4 aut | |
| 700 | 1 | |a Hassel, Jessica C. |d 1975- |e VerfasserIn |0 (DE-588)129790702 |0 (DE-627)480399069 |0 (DE-576)29783715X |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer immunology immunotherapy |d Berlin : Springer, 1976 |g 71(2022), 8, Seite 2051-2056 |h Online-Ressource |w (DE-627)253390443 |w (DE-600)1458489-X |w (DE-576)072283475 |x 1432-0851 |7 nnas |a Immune-related adverse events of COVID-19 vaccination in skin cancer patients receiving immune-checkpoint inhibitor treatment |
| 773 | 1 | 8 | |g volume:71 |g year:2022 |g number:8 |g pages:2051-2056 |g extent:6 |a Immune-related adverse events of COVID-19 vaccination in skin cancer patients receiving immune-checkpoint inhibitor treatment |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s00262-021-03133-w |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20230606 | ||
| 993 | |a Article | ||
| 994 | |a 2022 | ||
| 998 | |g 129790702 |a Hassel, Jessica C. |m 129790702:Hassel, Jessica C. |d 910000 |d 911300 |d 50000 |e 910000PH129790702 |e 911300PH129790702 |e 50000PH129790702 |k 0/910000/ |k 1/910000/911300/ |k 0/50000/ |p 4 |y j | ||
| 998 | |g 1262091551 |a Kälber, Katharina |m 1262091551:Kälber, Katharina |d 910000 |d 911300 |e 910000PK1262091551 |e 911300PK1262091551 |k 0/910000/ |k 1/910000/911300/ |p 3 | ||
| 998 | |g 1165195224 |a Machiraju, Devayani |m 1165195224:Machiraju, Devayani |d 910000 |d 911300 |e 910000PM1165195224 |e 911300PM1165195224 |k 0/910000/ |k 1/910000/911300/ |p 2 | ||
| 998 | |g 1034652141 |a Strobel, Sophia |m 1034652141:Strobel, Sophia |d 910000 |d 910100 |e 910000PS1034652141 |e 910100PS1034652141 |k 0/910000/ |k 1/910000/910100/ |p 1 |x j | ||
| 999 | |a KXP-PPN1847534716 |e 4329679728 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"id":{"eki":["1847534716"],"doi":["10.1007/s00262-021-03133-w"]},"title":[{"title_sort":"Immune-related adverse events of COVID-19 vaccination in skin cancer patients receiving immune-checkpoint inhibitor treatment","title":"Immune-related adverse events of COVID-19 vaccination in skin cancer patients receiving immune-checkpoint inhibitor treatment"}],"recId":"1847534716","note":["Gesehen am 06.06.2023"],"language":["eng"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"origin":[{"dateIssuedKey":"2022","dateIssuedDisp":"23 December 2021"}],"name":{"displayForm":["Sophia B. Strobel, Devayani Machiraju, Katharina A. Kälber, Jessica C. Hassel"]},"person":[{"roleDisplay":"VerfasserIn","family":"Strobel","given":"Sophia","display":"Strobel, Sophia","role":"aut"},{"given":"Devayani","role":"aut","display":"Machiraju, Devayani","roleDisplay":"VerfasserIn","family":"Machiraju"},{"given":"Katharina","role":"aut","display":"Kälber, Katharina","family":"Kälber","roleDisplay":"VerfasserIn"},{"roleDisplay":"VerfasserIn","family":"Hassel","display":"Hassel, Jessica C.","role":"aut","given":"Jessica C."}],"physDesc":[{"extent":"6 S."}],"relHost":[{"origin":[{"publisherPlace":"Berlin ; Heidelberg","dateIssuedKey":"1976","dateIssuedDisp":"1976-","publisher":"Springer"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"language":["eng"],"physDesc":[{"extent":"Online-Ressource"}],"part":{"extent":"6","year":"2022","pages":"2051-2056","text":"71(2022), 8, Seite 2051-2056","volume":"71","issue":"8"},"title":[{"title":"Cancer immunology immunotherapy","title_sort":"Cancer immunology immunotherapy","subtitle":"CII"}],"id":{"issn":["1432-0851"],"eki":["253390443"],"zdb":["1458489-X"]},"note":["Gesehen am 15.05.2024","Fortsetzung der Druck-Ausgabe","Ungezählte Beil. ab 52.2003: Supplement"],"disp":"Immune-related adverse events of COVID-19 vaccination in skin cancer patients receiving immune-checkpoint inhibitor treatmentCancer immunology immunotherapy","recId":"253390443","pubHistory":["1.1976 -"],"titleAlt":[{"title":"CII"}]}]} | ||
| SRT | |a STROBELSOPIMMUNERELA2320 | ||